Molecular and Cellular Functions of S100A10: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Gillian C. Okura
,
Alamelu G. Bharadwaj
,
David M. Waisman

S100A10 (p11, annexin II light chain, calpactin light chain) is a multifunctional protein with a wide range of physiological activity. S100A10 is unique among the S100 family members of proteins since it does not bind to Ca2+, despite its sequence and structural similarity. 

  • S100A10
  • Ca2+-binding
  • fibrinolysis
  • cancer
  • depression

1. Binding Partners of S100A10

In addition to annexin A2, several additional proteins have been shown to interact with S100A10. The physiological significance remains unknown for most of these protein–protein interactions. Additionally, it is unclear if S100A10 is the only protein in the S100 family that will interact with these proteins. A list of published S100A10 protein interactors was generated by summarizing public databases: NCBI (https://www.ncbi.nlm.nih.gov/), BioGRID (https://thebiogrid.org/) and ELIXIR (https://www.ebi.ac.uk/intact/home). Ontology analysis of the protein interactors was performed using DAVID 7.0 [1] (http://david.ncifcrf.gov/). Significant ontology findings with a p value < 0.05 and FDR < 0.1 are summarized in Table 1 and illustrated in Figure 1. Interactions that have been demonstrated to have physiological relevance are presented in Table 2. 
Figure 1. The list of S100A10 interacting proteins was subjected to gene ontology analysis in DAVID 7.0 to characterize putative biological activity. Gene ontology analysis indicated that S100A10 interacting proteins are ubiquitous in the cell and are involved in many vital processes. Biological processes (BP), molecular functions (MF), and cellular component (CC) ontology results with a p value < 0.05 and FDR < 0.1 are summarized. ANXA2 (annexin A2). Created with “Biorender.com (accessed on 6 August 2023)”.
Table 1. Binding partners participating in different S100A10-related functions.
GO Classification Ontology Terms Proteins
Biological process Negative regulation of apoptotic process (GO:0043066) EGFR, ERBB3, ERBB4, FLNA, GDNF, KIF14, MYC, NPM1, PLA2R, PPIF, RAF1, SIN3A, TNF, TP53
Biological Process mRNA transcription from RNA polymerase II promoter (GO:0042789) ANXA2, ATF2, HLTF, S100A10, SUPT6H
Cellular component Plasma membrane region (GO:0098590) EGFR, ERBB3, ERBB4, PLD1
Cellular component Midbody (GO:0030496) ANLN, ANXA2, CHMP4B, CHMP4C, CIT, ECT2, KIF14, KIF20A, PRC1
Cellular component Plasma membrane (GO:0005886) 5-HTR1B, 5-HTR1D, 5-HTR4, AHNAK, ANTXR1, ANXA2, ASIC-1 channels, CCR10, CD55, CD81, CDK16, CFTR, CHMP4B, CHMP4C, EGFR, ERBB3, ERBB4, ESR1, FLNA, FLOT1, FSHR, GOLGA4, HDLBP, HSPA8, KCNK3, KIF14, LIMA1, MAEA, MAPT, mGluR5, MLKL, MMGT1, MYH9, Myo1c, NaV1.8 sodium channel, OR14I1, OR4N2, PDYN, PIK3R6, PLA2G4C, PLA2R, PLD1, PLG, PRC1, RAF1, S100A10, S100A3, S100A8, SLC8A1, TMEM65, TNF, TNFRSF10A, Transglutaminase, TRPM4, TRPV5, TRPV6, ZGPAT
Cellular component Basal plasma membrane (GO:0009925) CD81, EGFR, ERBB3, ERBB4, Myo1c
Cellular component Nuclear matrix (GO:0016363) ANXA2, HLTF, MAEA, PHF5A, S100A10, TP53
Cellular component Actin cytoskeleton (GO:0015629) AHNAK, ANG, ANLN, FLNA, LIMA1, MYH9, Myo1c, NEB
Cellular component An integral component of the plasma membrane (GO:0005887) 5-HTR1B, 5-HTR1D, 5-HTR4, ASIC-1 channels, CCR10, CD81, CFTR, EGFR, ERBB3, ERBB4, FSHR, KCNK3, MAEA, mGluR5, PLA2R, SLC8A1, TNF, TRPM4, TRPV5, TRPV6
Cellular component Lysosomal membrane (GO:0005765) AHNAK, ANXA2, ATP6V1E1, CFTR, CHMP4B, CHMP4C, FLOT1, HSPA8, PLD1
Cellular component Endosome (GO:0005768) 5-HTR4, ANXA2, ATP6V1E1, CHMP4B, EGFR, FLOT1, FSHR, PLD1
Molecular function Calcium-dependent protein binding (GO:0048306) ANXA2, S100A10, S100A3, S100A7, S100A8, S100Z
Molecular function Zinc ion binding (GO:0008270) BMI1, ESR1, HDAC4, HDAC6, HLTF, NANOS2, NBR1, PHF5A, Q6ZTA4, Q96KR1, S100A3, S100A7, S100A8, SETDB1, TP53, TRIM37, ZCCHC9
Molecular function Promoter-specific chromatin binding (GO:1990841) ATF2, BMI1, HDAC4, SETDB1, TP53
Molecular function ATP binding (GO:0005524) HSPA8, KIF14, KIF20A, MLKL, MYH9, Myo1c, NARS1, NaV1.8 sodium channel, RAF1, SLFN14
Molecular function Enzyme binding (GO:0019899) CFTR, EGFR, ESR1, HDAC6, HSPA8, MAPT, PLA2R, PLG, RAF1, TP53
Molecular function Actin binding (GO:0003779) ANG, ANLN, DYRK1A, HDAC6, MAEA, MAPT, MYH9, Myo1c, NEB
Molecular function Calmodulin binding (GO:0005516) ESR1, MYH9, Myo1c, SLC8A1, TRPM4, TRPV5, TRPV6
Molecular function Serotonin binding (GO:0051378) 5-HTR1B, 5-HTR1D, 5-HTR4
Table 2. Proteins with known functional interactions with p11.
Interactor Protein Name Uniprot Accession Cellular Location Method References
5-HTR1B 5-hydroxytryptamine receptor 1B P28222 Plasma membrane Two-hybrid [2][3]
5-HTR1D 5-hydroxytryptamine receptor 1D P28221 Plasma membrane Two-hybrid [3]
5-HTR4 5-hydroxytryptamine receptor 4 Q13639 Plasma membrane Two-hybrid [3]
AHNAK Neuroblast differentiation-associated protein AHNAK Q09666 Nucleus AC-MS 1; AC-W 2; Co-crystal structure; Co-fractionation; PL-MS 3 [4][5][6][7]
ANXA2 Annexin A2 P07355 Nucleus; Cytoplasm; Plasma membrane; Extracellular AC-MS 1; AC-W 2; Co-crystal structure; Co-fractionation; PL-MS 3; Reconstituted complex; Two-hybrid [5][7][8][9][10][11][12][13][14][15][16][17][18][19]
ASIC-1 channels Acid-sensing ion channel 1 P78348 Plasma membrane Two hybrid [20]
BAD BCL2-associated agonist of cell death Q92934 Cytoplasm Reconstituted complex; Two-hybrid [21]
Cathepsin B Cathepsin B P07858 Cytoplasm; Plasma membrane; Extracellular Two hybrid: Reconstituted complex [22]
Cytosolic Phospholipase A2   Q9UP65 Cytoplasm: Plasma membrane Two-hybrid [23]
NaV1.8 Sodium channel protein type 8 subunit α Q9UQD0 Plasma membrane Two-hybrid [24]
PCTAIRE-1 Cyclin-dependent kinase 16 Q00536 Cytoplasm Two-hybrid [25]
Plg Plasminogen P00747 Extracellular AC-W 2; Surface plasmon resonance [26][27]
S100A7 Protein S100-A7 P31151 Cytoplasm; Extracellular AC-MS 1 [28]
S100A8 Protein S100-A8 P05109 Plasma membrane; Cytoplasm; Extracellular AC-MS 1 [28]
TASK-1 Potassium channel subfamily K member 3 O14649 Plasma membrane Two-hybrid [29][30]
TRPV5 Transient receptor potential cation channel subfamily V member 5 Q9NQA5 Plasma membrane Reconstituted complex; Two-hybrid [31]
TRPV6 Transient receptor potential cation channel subfamily V member 6 Q9H1D0 Plasma membrane Reconstituted complex [31]
Transglutaminase Protein-glutamine-γ-glutamyltransferase K & 2. P22735; P08587 Plasma membrane; Cytoplasm AC-W 2 [32]
1—Affinity Capture—Mass Spectrometry, 2—Affinity Capture—Western Blot, 3—Proximity Label—Mass Spectrometry.
To date, over 170 proteins have been proposed to interact with S100A10 and observed through various biochemical approaches. Mass spectrometry was the most commonly used technique to identify S100A10 interactors. This approach involved several techniques, including affinity capture (34% of identified interactors), proximity labeling (13%), and co-fractionation (13%). Two-hybrid yeast screening was the second most popular biochemical approach to identify interactors (13%). Other methods used to identify protein interactors included, but were not limited to, co-crystal structure, affinity capture-western blot, reconstituted complex, co-immunoprecipitation, and fluorescent imaging. It will be interesting to determine the physiological relevance of the predicted binding partners of S100A10 and, more specifically, to identify the binding regions or structural determinants in S100A10 that predict and demonstrate the binding affinity to the various proteins.

2. Regulation of S100A10

The expression and function of S100A10 are tightly regulated by various cytokines, growth factors, nitric oxide (reviewed in [33]), RAS oncogene [34], PML-RAR oncogene [35], and hypoxia-inducible factor (HIF) [36]. Annexin A2 is also an important regulator of S100A10, and S100A10 also regulates the properties of annexin A2, a process called mutualistic symbiosis . MicroRNA (miRNA) and long-non-coding RNA (LncRNA) are important non-protein-coding RNA machinery that make up a large percentage of the genome. They have been demonstrated to function in post-transcriptional and epigenetic regulation. LncRNA and miRNA play a crucial role in regulating development, stress-mediated processes, immune response and tumor progression, metastasis, and chemoresistance [37][38][39][40]. Most evidence of the regulation of S100A10 by miRNA and LncRNA has been obtained from studies in hepatocellular carcinoma (HCC) models. Shan et al. identified that mir-590-5p is decreased in some hepatocellular carcinoma cell lines with a concomitant upregulation of S100A10. They further showed that mir-590-5p regulated S100A10 expression by interacting with the 3′UTR of S100A10 mRNA [41]. Similarly, LINC00174 has been shown to be an oncogenic LncRNA in HCC, and it functions by sponging mir-320, which further upregulates the expression of S100A10, accelerating the proliferation and metastasis of HCC cells [42]. Another lncRNA, KCNMB2-AS1, functions by regulating S100A10 in bladder cancer through direct sponging of miR-374a-3p, which negatively regulates the expression of S100A10 [43]. 

3. Role of p11 in Fibrinolysis

S100A10 is present at the endothelial cell surface and bound to annexin A2, forming the AIIt complex . This complex has been shown to be one of the key plasminogen-binding receptor proteins on the surface of endothelial cells. The S100A10 subunit binds plasminogen, whereas the annexin A2 subunit anchors the complex to the cell surface . The role of AIIt in fibrinolysis was confirmed by studies of the S100A10-knockout mouse, where it was observed that S100A10-null mice displayed increased deposition of fibrin in the vasculature and reduced clearance of experimentally-induced vascular thrombi . Plasminogen (Pg) is an inactive zymogen that is converted to the active serine protease plasmin (Pm) by plasminogen activators, tissue-plasminogen (tPA) activators, and urokinase plasminogen activator (uPA). This process is highly regulated; the principal inhibitor of Pm is α2-antiplasmin (AP), and the principal inhibitor of tPA and uPA is plasminogen activator inhibitor type 1 (PAI-1) [44][45][46][47]. Although tPA and uPA possess low activity, their activity dramatically increases when interacting with Pg receptors. Certain Pg receptors also protect Pg activators and Pm from inactivation. Thus, Pg receptors such as AIIt are the key regulators of Pm generation.
Plasmin is crucial for dissolving fibrin clots in a process known as fibrinolysis. Fibrin blood clot formation begins when a break in a blood vessel allows plasma to contact tissue factors in the extracellular matrix. Initially, factor VII binds to tissue factor and is activated, which participates in the activation of a clotting factor cascade and results in the cleavage of prothrombin into thrombin. This thrombin activates platelets, resulting in the generation of FXa/Va complexes and the generation of sufficient thrombin from prothrombin to convert fibrinogen to fibrin, resulting in the formation of a stable hemostatic plug [48][49]. The fibrinolytic surveillance system is critical in preventing the inappropriate formation of blood clots and in regulating the size of blood clots that form at the site of injury. Fibrinolysis is initiated by the secretion of plasminogen activators (tPA and uPA). The endothelium of blood vessels secretes tPA, which circulates in the blood as a single-chain protein (sct-PA). The kidney secretes uPA, which circulates in an inactive single-chain form (scu-PA), which Pm must convert into the active two-chain form (tcu-PA) [50][51].
Pm degrades the fibrin blood clot, producing D-dimer and other fibrin degradation products. Impaired breakdown of fibrin clots is associated with many diseases, including diabetes, insulin resistance, sepsis, stroke, and the metabolic syndrome [52][53][54][55]. Impaired fibrinolysis also contributes to deep venous thrombosis and pulmonary embolism [56]. Impaired fibrinolysis is a feature of ischemic stroke and is present in both the acute and convalescent phases of the disease [57][58][59].

4. Neurological Functions

Previous reviews of S100A10 have uncovered new insight into the protein’s role in regulating mood-related behavior [60]. S100A10 has been implicated in the pathophysiology of depression and is being examined as a critical modulator of neurological functions [60]. Several G protein-coupled receptors, channels, and transporters have been identified to interact with S100A10, including serotonin 5-HT receptors [2], metabotropic glutamate receptor mGluR5 [61], Na2+ ion channel NaV1.8 [24], acid-sensing channel ASIC-1 [20], K+ channel subfamily K member 3 (TASK-1) [29][30], and transient receptor potential cation Ca2+ channels subfamily TRPV5 and TRPV6 [31]. Global proteomic screens have additionally identified C-C chemokine receptor type 10 (CCR10) [62], flotillin-1 (FLOT1) [6], follicle-stimulating hormone receptor (FSHR) [63], olfactory receptor 4N2 (OR4N2), and 4N1 (OR14l1) [5] as S100A10 interactors.
S100A10 expression is widespread in the brain and spans multiple structures and cell types. Milosevic et al. suggest that the expression is distinct to specific regions when comparing neuronal and nonneuronal cell types [64]. Some identified areas include the hippocampus [7][65], amygdala [65], cerebral cortex [66], anterior cingulate cortex [2], and nucleus accumbens [67]. The expression of S100A10 in the brain has been extensively examined for its role in modulating mood-related behaviors, including major depressive disorder, Parkinson’s disease, and other neuropsychiatric disorders [68][69].
The role of S100A10 in depression and as a regulator of the antidepressant response has been examined in various mouse and human studies. Reduced S100A10 expression in multiple brain regions in depressed individuals implicated S100A10′s role in depression pathology [2][65][70]. Epigenetic studies of S100A10 propose it as a biomarker to predict treatment response and diagnose depressive-like behavior. Expression of S100A10 can be regulated by various factors, such as antidepressants, nitric oxide, growth factors, and dexamethasone [71][72]. While S100A10 is reduced in brain tissue from depressed patients, S100A10 expression increases in the peripheral blood. One study comparing S100A10 expression levels by quantitative PCR found that compared to healthy patients, depressed and high-stressed individuals studied had higher expression of S100A10 in their blood cells [73].
The S100A10-knock-out mouse models have been instrumental in studying the function of S100A10 in depression, mood disorders, and anxiety. In one of the first hallmark studies, Svenningson et al. showed that S100A10-depleted mice demonstrate depression-like behaviors, and S100A10 expression is increased in rodent brains after anti-depressant therapy. S100A10 mediates its function in depression via interaction with the serotonin 1B receptor [5-hydroxytrptamin (5HT1B) receptor] [2]. More recently, Seo et al. observed that S100A10 is a key protein that modulates chronic stress-induced depression in rodent models, and anti-depressants reverse this phenotype by upregulating S100A10 in the prelimbic cortex (PrL) [72]. Furthermore, they showed that S100A10 in ependymal cells regulates depressive states in chronic stress by modulating the flow of cerebrospinal fluid (CSF) by maintaining the planar cell polarity in ependymal cells [72].

5. Inflammation and Wound Healing

The plasminogen activation system and S100A10 play an integral role in the inflammatory process. S100A10 functions on the plasma membrane and in the extracellular space, correlated with the immune response and regulation of immune activities [74]. The Ca2+ binding activity of S100A proteins plays an important role during the inflammatory process by regulating different molecules and inflammatory signaling pathways that lead to inflammation [75][76]. S100 isoforms can contribute to the immune response as pro-inflammatory stimulators, chemo-attractants, and antimicrobial peptides [74].
During inflammation and wound healing processes, extracellular matrix (ECM) degradation is a vital step, and the S100A10 dimer component of Allt is a crucial molecule in the process [75]. Pg binds to the S100A10 dimer of Allt, and plasminogen activators tPA and uPA mediate its activation into Pm, which can initiate downstream proteolytic cascades associated with the wound repair process [22][26][77][78][79][80]. This S100A10-mediated protease activation is utilized by highly motile cells, such as metastatic cancer cells and macrophages, to facilitate its migration through the ECM [78][80][81][82][83][84][85][86][87].
Macrophages play a critical role in the pathogenic inflammatory response by initiating, maintaining, and resolving inflammation processes [83][88]. Cell-surface generation of plasmin is required for macrophage recruitment [89]. This recruitment is partly mediated through the plasmin-dependent activation of matrix metallopeptidase 9 (MMP-9) [83][89]. Activation of plasmin occurs through four plasminogen receptors found on the cell surface, including S100A10 [26][77][90][91], α-enolase [92], Plg-RKT [93], and histone H2B [94].
The researchers have previously demonstrated a direct involvement of S100A10 in response to inflammatory stimuli to recruit macrophages [83]. P11 was up-regulated in macrophages that were activated by inflammatory mediators. Thioglycollate-stimulated peritoneal macrophages had higher S100A10 and annexin A2 protein levels when compared to resident peritoneal macrophages. In S100A10-/- mice, macrophage migration into the peritoneal cavity across the peritoneal membrane was decreased. S100A10 and the other carboxyl-terminal Pg receptors contribute to Pm generation in macrophages, which allows macrophages to play a role in directly facilitating the proteolysis of the basement membrane, hydrolyzing ECM proteins, and activating MMP-9 during inflammatory responses [83].
S100A10 can also activate human and murine macrophages directly through the toll-like receptor 4 (TLR4) pathway [95][96]. Cell surface Pm generated by Allt can trigger the phosphorylation of PKC signaling molecules, which can activate mitogen-activated protein kinase (MAPK), TLR4, and NFκB signaling pathways [95]. Allt disassembly after Allt phosphorylation can activate the CD11b-dependent integrin-linked kinase (ILK) pathway [97], which, together with Pm, can induce NFκB nuclear translocation and promote pro-inflammatory factor production [95][98][99]. The release of these pro-inflammatory cytokines, including IL-1, IL-6, and TNFα, can facilitate immune-escape mechanisms by evading immunosurveillance and mitigating T cell cytotoxicity [95][98][99]. Allt-driven cytokine production is inhibited by TLR-4 knockdown [95], which suggests that TLR-4 is important for Allt-mediated inflammation.
More recently, S100A10 has been examined for its role in the inflammatory condition of COVID-19 patients. The S100 family of proteins has been suggested to be able to direct more monocytes and neutrophils to the target site of COVID-19 patients by controlling the cytokine release syndrome [76]. A study comparing NK and NK-T cell subsets between COVID-19 patients and healthy individuals identified S100A10 as a marker for COVID-19-derived NK-T cells [100]. Disease trajectory transcriptomic models of COVID-19 severity from peripheral mononuclear cells found that genes encoding Ca2+-binding proteins play important roles in regulating inflammatory pathways; however, p11 was not indicated as one of the S100 proteins involved [101]. Another study looking at peripheral blood samples from COVID-19 cases observed an upregulation of S100A10, S100A4, and S100A9 mRNA [76].

6. Exocytosis and Trafficking

The AIIt complex has long been implicated at the plasma membrane to play a role in early and late secretory events and membrane-cytoskeleton lineage [9][102][103]. At the cell membrane, the AIIt complex was found localized to the contact site of the plasma membrane/secretory granule, suggesting it played a role in the exocytotic process of the cell [104][105][106][107]. While the crosslinking activity of the AIIt complex is necessary for efficient, regulated exocytosis, it is not an obligatory component [103]. The exocytotic machinery of the Allt complex is Ca2+ sensitive [108] and is more efficient than monomeric annexin protein in regulating Ca2+-dependent exocytosis [104][109][110]. These features and functions of the AIIt complex have played an important role in the pathogenesis of many viruses, such as HBV, HPV, and HIV-1 [111][112][113][114][115]. The AIIt complex has been shown to facilitate the exocytosis of von Willebrand factor (vWF) in vascular endothelial cells [116][117], the release of the bluetongue virus (BTV) in BHK21 cells [118][119], and the human papillomavirus type 16 in human keratinocytes [120]. Finally, recent studies by Bai et al. have shown that the AIIt complex promotes hepatitis B virus (HBV) exocytosis in the trophoblasts by recruiting VAMP2 and SNAP25 for membrane fusion events [111].

7. Autophagy and Metabolism

Cancer cells require increased metabolism to maintain sustained proliferative growth and spread. S100A10 can respond to a variety of signals to maintain and accelerate cancer cell metabolism. Members of the S100 family of proteins are involved in a number of metabolic functions, including redox, energy, and sugar metabolism [121]. S100A10 has been shown to increase the malignant growth of cancer cells by activating the mTOR signaling pathway in osteosarcoma [122], gastric cancer [123], pancreatic ductal adenocarcinoma (PDAC) [124][125], and HCC [126][127]. Li et al. reported that S100A10, through its interaction with annexin A2, accelerated tumor glycolysis and lactate production and contributed to the switch from oxidative phosphorylation to aerobic glycolysis [123]. Glucose consumption was significantly increased in S100A10-overespressing cells and reduced in S100A10-knockout cells. This overexpression of S100A10 also reduced the amount of intracellular ATP production, indicating the important role of S100A10 in facilitating glycolysis. By modulating the Src/annexin A2/AKT/mTOR signaling pathway, S100A10 could promote pro-tumor aerobic glycolysis, suppress cell apoptosis, and maintain cell proliferation.
S100A10 knockdown was also shown to affect the malignant growth of osteosarcoma cells by modulating glycolysis [122]. Knockdown of S100A10 in the osteosarcoma cell line inhibited proliferation, migration, and invasion and induced apoptosis via the AKT/mTOR pathway by modulating glycolysis. S100A10 played a critical role in HCC progression through the epithelial-mesenchymal transition by upregulating the epidermal growth factor receptor and AKT/ERK signaling pathways. Furthermore, Lin et al. showed that S100A10 could activate LAMB3 through the JNK pathway in PANC-1 cells [124]. By activating the JNK/LAMB3-LAMC2 axis, S100A10 was able to promote PDAC cell proliferation, migration, and adhesion.

This entry is adapted from the peer-reviewed paper 10.3390/biom13101450

References

  1. Huang, D.W.; Sherman, B.T.; Lempicki, R.A. Systematic and Integrative Analysis of Large Gene Lists Using DAVID Bioinformatics Resources. Nat. Protoc. 2009, 4, 44–57.
  2. Svenningsson, P.; Chergui, K.; Rachleff, I.; Flajolet, M.; Zhang, X.; Yacoubi, M.E.; Vaugeois, J.-M.; Nomikos, G.G.; Greengard, P. Alterations in 5-HT1B Receptor Function by P11 in Depression-Like States. Science 2006, 311, 77–80.
  3. Warner-Schmidt, J.L.; Flajolet, M.; Maller, A.; Chen, E.Y.; Qi, H.; Svenningsson, P.; Greengard, P. Role of P11 in Cellular and Behavioral Effects of 5-HT4 Receptor Stimulation. J. Neurosci. 2009, 29, 1937–1946.
  4. Benaud, C.; Gentil, B.J.; Assard, N.; Court, M.; Garin, J.; Delphin, C.; Baudier, J. AHNAK Interaction with the Annexin 2/S100A10 Complex Regulates Cell Membrane Cytoarchitecture. J. Cell Biol. 2004, 164, 133–144.
  5. Fasci, D.; van Ingen, H.; Scheltema, R.A.; Heck, A.J.R. Histone Interaction Landscapes Visualized by Crosslinking Mass Spectrometry in Intact Cell Nuclei. Mol. Cell Proteom. 2018, 17, 2018–2033.
  6. Havugimana, P.C.; Hart, G.T.; Nepusz, T.; Yang, H.; Turinsky, A.L.; Li, Z.; Wang, P.I.; Boutz, D.R.; Fong, V.; Phanse, S.; et al. A Census of Human Soluble Protein Complexes. Cell 2012, 150, 1068–1081.
  7. Oh, Y.-S.; Gao, P.; Lee, K.-W.; Ceglia, I.; Seo, J.-S.; Zhang, X.; Ahn, J.-H.; Chait, B.T.; Patel, D.J.; Kim, Y.; et al. SMARCA3, a Chromatin-Remodeling Factor, Is Required for P11-Dependent Antidepressant Action. Cell 2013, 152, 831–843.
  8. Bailleux, A.; Wendum, D.; Audubert, F.; Jouniaux, A.-M.; Koumanov, K.; Trugnan, G.; Masliah, J. Cytosolic Phospholipase A2-P11 Interaction Controls Arachidonic Acid Release as a Function of Epithelial Cell Confluence. Biochem. J. 2004, 378, 307–315.
  9. Gerke, V.; Weber, K. Identity of p36K Phosphorylated upon Rous Sarcoma Virus Transformation with a Protein Purified from Brush Borders; Calcium-Dependent Binding to Non-Erythroid Spectrin and F-Actin. EMBO J. 1984, 3, 227–233.
  10. Havugimana, P.C.; Goel, R.K.; Phanse, S.; Youssef, A.; Padhorny, D.; Kotelnikov, S.; Kozakov, D.; Emili, A. Scalable Multiplex Co-Fractionation/Mass Spectrometry Platform for Accelerated Protein Interactome Discovery. Nat. Commun. 2022, 13, 4043.
  11. He, K.-L.; Deora, A.B.; Xiong, H.; Ling, Q.; Weksler, B.B.; Niesvizky, R.; Hajjar, K.A. Endothelial Cell Annexin A2 Regulates Polyubiquitination and Degradation of Its Binding Partner S100A10/P11. J. Biol. Chem. 2008, 283, 19192–19200.
  12. Hein, M.Y.; Hubner, N.C.; Poser, I.; Cox, J.; Nagaraj, N.; Toyoda, Y.; Gak, I.A.; Weisswange, I.; Mansfeld, J.; Buchholz, F.; et al. A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances. Cell 2015, 163, 712–723.
  13. Huttlin, E.L.; Ting, L.; Bruckner, R.J.; Gebreab, F.; Gygi, M.P.; Szpyt, J.; Tam, S.; Zarraga, G.; Colby, G.; Baltier, K.; et al. The BioPlex Network: A Systematic Exploration of the Human Interactome. Cell 2015, 162, 425–440.
  14. Huttlin, E.L.; Bruckner, R.J.; Paulo, J.A.; Cannon, J.R.; Ting, L.; Baltier, K.; Colby, G.; Gebreab, F.; Gygi, M.P.; Parzen, H.; et al. Architecture of the Human Interactome Defines Protein Communities and Disease Networks. Nature 2017, 545, 505–509.
  15. Huttlin, E.L.; Brukner, R.J.; Navarrete-Perea, J.; Cannon, J.R.; Baltier, K.; Gebreab, F.; Gygi, M.P.; Thornock, A.; Zarraga, G.; Tam, S.; et al. Dual Proteome-Scale Networks Reveal Cell-Specific Remodeling of the Human Interactome. Cell 2021, 184, 3022–3040.e28.
  16. Réty, S.; Sopkova, J.; Renouard, M.; Osterloh, D.; Gerke, V.; Tabaries, S.; Russo-Marie, F.; Lewit-Bentley, A. The Crystal Structure of a Complex of P11 with the Annexin II N-Terminal Peptide. Nat. Struct. Biol. 1999, 6, 89–95.
  17. Tian, W.; Wijewickrama, G.T.; Kim, J.H.; Das, S.; Tun, M.P.; Gokhale, N.; Jung, J.W.; Kim, K.P.; Cho, W. Mechanism of Regulation of Group IVA Phospholipase A2 Activity by Ser727 Phosphorylation. J. Biol. Chem. 2008, 283, 3960–3971.
  18. Waisman, D.M. Annexin II Tetramer: Structure and Function. Mol. Cell Biochem. 1995, 149/150, 301–322.
  19. Zobiack, N.; Rescher, U.; Ludwig, C.; Zeuschner, D.; Gerke, V. The Annexin 2/S100A10 Complex Controls the Distribution of Transferrin Receptor-Containing Recycling Endosomes. MBoC 2003, 14, 4896–4908.
  20. Donier, E.; Rugiero, F.; Okuse, K.; Wood, J.N. Annexin II Light Chain P11 Promotes Functional Expression of Acid-Sensing Ion Channel ASIC1a. J. Biol. Chem. 2005, 280, 38666–38672.
  21. Hsu, S.Y.; Kaipia, A.; McGee, E.; Lomeli, M.; Hsueh, A.J.W. Bok Is a Pro-Apoptotic Bcl-2 Protein with Restricted Expression in Reproductive Tissues and Heterodimerizes with Selective Anti-Apoptotic Bcl-2 Family Members. Proc. Natl. Acad. Sci. USA 1997, 94, 12401–12406.
  22. Mai, J.; Waisman, D.M.; Sloane, B.F. Cell Surface Complex of Cathepsin B/Annexin II Tetramer in Malignant Progression. Biochim. Biophys. Acta 2000, 1477, 215–230.
  23. Wu, T.; Angus, C.W.; Yao, X.-L.; Logun, C.; Shelhamer, J.H. P11, a Unique Member of the S100 Family of Calcium-Binding Proteins, Interacts with and Inhibits the Activity of the 85-kDa Cytosolic Phospholipase A2. J. Biol. Chem. 1997, 272, 17145–17153.
  24. Okuse, K.; Malik-Hall, M.; Baker, M.D.; Poon, W.-Y.L.; Kong, H.; Chao, M.V.; Wood, J.N. Annexin II Light Chain Regulates Sensory Neuron-Specific Sodium Channel Expression. Nature 2002, 417, 653–656.
  25. Le Bouffant, F.; Capdevielle, J.; Guillemot, J.-C.; Sladeczek, F. Characterization of Brain PCTAIRE-1 Kinase Immunoreactivity and Its Interactions with P11 and 14-3-3 Proteins. Eur. J. Biochem. 1998, 257, 112–120.
  26. Kassam, G.; Le, B.-H.; Choi, K.-S.; Kang, H.-M.; Fitzpatrick, S.L.; Louie, P.; Waisman, D.M. The P11 Subunit of the Annexin II Tetramer Plays a Key Role in the Stimulation of T-PA-Dependent Plasminogen Activation. Biochemistry 1998, 37, 16958–16966.
  27. Fogg, D.K.; Bridges, D.E.; Cheung, K.K.-T.; Kassam, G.; Filipenko, N.R.; Choi, K.-S.; Fitzpatrick, S.L.; Nesheim, M.; Waisman, D.M. The P11 Subunit of Annexin II Heterotetramer Is Regulated by Basic Carboxypeptidase. Biochemistry 2002, 41, 4953–4961.
  28. Lehmann, R.; Melle, C.; Escher, N.; Von Eggeling, F. Detection and Identification of Protein Interactions of S100 Proteins by ProteinChip Technology. J. Proteome Res. 2005, 4, 1717–1721.
  29. Girard, C.; Tinel, N.; Terrenoire, C.; Romey, G.; Lazdunski, M.; Borsotto, M. P11, an Annexin II Subunit, an Auxiliary Protein Associated with the Background K+ Channel, TASK-1. EMBO J. 2002, 21, 4439–4448.
  30. Renigunta, V.; Yuan, H.; Zuzarte, M.; Rinné, S.; Koch, A.; Wischmeyer, E.; Schlichthörl, G.; Gao, Y.; Karschin, A.; Jacob, R.; et al. The Retention Factor P11 Confers an Endoplasmic Reticulum-Localization Signal to the Potassium Channel TASK-1. Traffic 2006, 7, 168–181.
  31. van de Graaf, S.F.J.; Hoenderop, J.G.J.; Gkika, D.; Lamers, D.; Prenen, J.; Rescher, U.; Gerke, V.; Staub, O.; Nilius, B.; Bindels, R.J.M. Functional Expression of the Epithelial Ca2+ Channels (TRPV5 and TRPV6) Requires Association of the S100A10-Annexin 2 Complex. EMBO J. 2003, 22, 1478–1487.
  32. Ruse, M.; Lambert, A.; Robinson, N.; Ryan, D.; Shon, K.-J.; Eckert, R.L. S100A7, S100A10, and S100A11 Are Transglutaminase Substrates. Biochemistry 2001, 40, 3167–3173.
  33. Głowacka, A.; Bieganowski, P.; Jurewicz, E.; Leśniak, W.; Wilanowski, T.; Filipek, A. Regulation of S100A10 Gene Expression. Biomolecules 2021, 11, 974.
  34. Madureira, P.A.; Bharadwaj, A.G.; Bydoun, M.; Garant, K.; O’Connell, P.; Lee, P.; Waisman, D.M. Cell Surface Protease Activation during RAS Transformation: Critical Role of the Plasminogen Receptor, S100A10. Oncotarget 2016, 7, 47720–47737.
  35. O’Connell, P.A.; Madureira, P.A.; Berman, J.N.; Liwski, R.S.; Waisman, D.M. Regulation of S100A10 by the PML-RAR-α Oncoprotein. Blood 2011, 117, 4095–4105.
  36. Lu, H.; Xie, Y.; Tran, L.; Lan, J.; Yang, Y.; Murugan, N.L.; Wang, R.; Wang, Y.J.; Semenza, G.L. Chemotherapy-Induced S100A10 Recruits KDM6A to Facilitate OCT4-Mediated Breast Cancer Stemness. J. Clin. Investig. 2020, 130, 4607–4623.
  37. Fernandes, J.; Acuña, S.; Aoki, J.; Floeter-Winter, L.; Muxel, S. Long Non-Coding RNAs in the Regulation of Gene Expression: Physiology and Disease. ncRNA 2019, 5, 17.
  38. Beermann, J.; Piccoli, M.-T.; Viereck, J.; Thum, T. Non-Coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol. Rev. 2016, 96, 1297–1325.
  39. He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a Big Role in Gene Regulation. Nat. Rev. Genet. 2004, 5, 522–531.
  40. Bartel, D.P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 2004, 116, 281–297.
  41. Shan, X.; Miao, Y.; Fan, R.; Qian, H.; Chen, P.; Liu, H.; Yan, X.; Li, J.; Zhou, F. MiR-590-5P Inhibits Growth of HepG2 Cells via Decrease of S100A10 Expression and Inhibition of the Wnt Pathway. Int. J. Mol. Sci. 2013, 14, 8556–8569.
  42. Zhao, J.; Chi, B.; Sun, Y.; Chi, N.; Zhang, X.; Sun, J.; Chen, Y.; Xia, Y. LINC00174 Is an Oncogenic lncRNA of Hepatocellular Carcinoma and Regulates miR-320/S100A10 Axis. Cell Biochem. Funct. 2020, 38, 859–869.
  43. Zhu, J.; Huang, Y.; Zhang, Y.; Huang, R.; Huang, C. KCNMB2-AS1 Promotes Bladder Cancer Progression Through Sponging miR-374a-3p to Upregulate S100A10. Front. Genet. 2021, 12, 655569.
  44. Medcalf, R.L. Fibrinolysis: From Blood to the Brain. J. Thromb. Haemost. 2017, 15, 2089–2098.
  45. Medcalf, R.L.; Keragala, C.B. The Fibrinolytic System: Mysteries and Opportunities. HemaSphere 2021, 5, e570.
  46. Ismail, A.A.; Shaker, B.T.; Bajou, K. The Plasminogen–Activator Plasmin System in Physiological and Pathophysiological Angiogenesis. Int. J. Mol. Sci. 2021, 23, 337.
  47. Longstaff, C.; Kolev, K. Basic Mechanisms and Regulation of Fibrinolysis. J. Thromb. Haemost. 2015, 13, S98–S105.
  48. Undas, A.; Ariëns, R.A.S. Fibrin Clot Structure and Function: A Role in the Pathophysiology of Arterial and Venous Thromboembolic Diseases. ATVB 2011, 31, e88–e99.
  49. Smith, S.A.; Travers, R.J.; Morrissey, J.H. How It All Starts: Initiation of the Clotting Cascade. Crit. Rev. Biochem. Mol. Biol. 2015, 50, 326–336.
  50. Hoylaerts, M.; Rijken, D.C.; Lijnen, H.R.; Collen, D. Kinetics of the Activation of Plasminogen by Human Tissue Plasminogen Activator. Role of Fibrin. J. Biol. Chem. 1982, 257, 2912–2919.
  51. Stump, D.C.; Lijnen, H.R.; Collen, D. Purification and Characterization of Single-Chain Urokinase-Type Plasminogen Activator from Human Cell Cultures. J. Biol. Chem. 1986, 261, 1274–1278.
  52. Anand, S.S.; Yi, Q.; Gerstein, H.; Lonn, E.; Jacobs, R.; Vuksan, V.; Teo, K.; Davis, B.; Montague, P.; Yusuf, S. Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation 2003, 108, 420–425.
  53. Fujii, S.; Goto, D.; Zaman, T.; Ishimori, N.; Watano, K.; Kaneko, T.; Okada, H.; Makiguchi, M.; Nakagawa, T.; Kitabatake, A. Diminished Fibrinolysis and Thrombosis: Clinical Implications for Accelerated Atherosclerosis. J. Atheroscler. Thromb. 1998, 5, 76–81.
  54. Mehra, A.; Ali, C.; Parcq, J.; Vivien, D.; Docagne, F. The Plasminogen Activation System in Neuroinflammation. Biochim. Biophys. Acta Mol. Basis Dis. 2016, 1862, 395–402.
  55. Schneider, D.J.; Nordt, T.K.; Sobel, B.E. Attenuated Fibrinolysis and Accelerated Atherogenesis in Type II Diabetic Patients. Diabetes 1993, 42, 1–7.
  56. Eichinger, S. D-Dimer Levels and Risk of Recurrent Venous Thromboembolism. JAMA 2003, 290, 1071.
  57. Rooth, E.; Wallen, N.H.; Blombäck, M.; He, S. Decreased Fibrin Network Permeability and Impaired Fibrinolysis in the Acute and Convalescent Phase of Ischemic Stroke. Thromb. Res. 2011, 127, 51–56.
  58. Feinberg, W.M.; Bruck, D.C.; Jeter, M.A.; Corrigan, J.J. Fibrinolysis after Acute Ischemic Stroke. Thromb. Res. 1991, 64, 117–127.
  59. Kataoka, S.; Hirose, G.; Hori, A.; Shirakawa, T.; Saigan, T. Activation of Thrombosis and Fibrinolysis Following Brain Infarction. J. Neurol. Sci. 2000, 181, 82–88.
  60. Svenningsson, P.; Kim, Y.; Warner-Schmidt, J.; Oh, Y.-S.; Greengard, P. P11 and Its Role in Depression and Therapeutic Responses to Antidepressants. Nat. Rev. Neurosci. 2013, 14, 673–680.
  61. Lee, K.-W.; Westin, L.; Kim, J.; Chang, J.C.; Oh, Y.-S.; Amreen, B.; Gresack, J.; Flajolet, M.; Kim, D.; Aperia, A.; et al. Alteration by P11 of mGluR5 Localization Regulates Depression-like Behaviors. Mol. Psychiatry 2015, 20, 1546–1556.
  62. Hessner, F.; Dlugos, C.P.; Chehab, T.; Schaefer, C.; Homey, B.; Gerke, V.; Weide, T.; Pavenstädt, H.; Rescher, U. CC Chemokine Receptor 10 Cell Surface Presentation in Melanocytes Is Regulated by the Novel Interaction Partner S100A10. Sci. Rep. 2016, 6, 22649.
  63. Cohen, B.D.; Nechamen, C.A.; Dias, J.A. Human Follitropin Receptor (FSHR) Interacts with the Adapter Protein 14-3-3τ. Mol. Cell. Endocrinol. 2004, 220, 1–7.
  64. Milosevic, A.; Liebmann, T.; Knudsen, M.; Schintu, N.; Svenningsson, P.; Greengard, P. Cell- and Region-Specific Expression of Depression-Related Protein P11 (S100a10) in the Brain. J. Comp. Neurol. 2017, 525, 955–975.
  65. Anisman, H.; Du, L.; Palkovits, M.; Faludi, G.; Kovacs, G.G.; Szontagh-Kishazi, P.; Merali, Z.; Poulter, M.O. Serotonin Receptor Subtype and P11 mRNA Expression in Stress-Relevant Brain Regions of Suicide and Control Subjects. J. Psychiatry Neurosci. 2007, 33, 131–141.
  66. Schmidt, E.F.; Warner-Schmidt, J.L.; Otopalik, B.G.; Pickett, S.B.; Greengard, P.; Heintz, N. Identification of the Cortical Neurons That Mediate Antidepressant Responses. Cell 2012, 149, 1152–1163.
  67. Warner-Schmidt, J.L.; Schmidt, E.F.; Marshall, J.J.; Rubin, A.J.; Arango-Lievano, M.; Kaplitt, M.G.; Ibañez-Tallon, I.; Heintz, N.; Greengard, P. Cholinergic Interneurons in the Nucleus Accumbens Regulate Depression-like Behavior. Proc. Natl. Acad. Sci. USA 2012, 109, 11360–11365.
  68. Chen, M.X.; Oh, Y.-S.; Kim, Y. S100A10 and Its Binding Partners in Depression and Antidepressant Actions. Front. Mol. Neurosci. 2022, 15, 1–10.
  69. Hedhli, N.; Falcone, D.J.; Huang, B.; Cesarman-Maus, G.; Kraemer, R.; Zhai, H.; Tsirka, S.E.; Santambrogio, L.; Hajjar, K.A. The Annexin A2/S100A10 System in Health and Disease: Emerging Paradigms. J. Biomed. Biotechnol. 2012, 2012, 406273.
  70. Alexander, B.; Warner-Schmidt, J.; Eriksson, T.M.; Tamminga, C.; Arango-Lievano, M.; Ghose, S.; Vernov, M.; Stavarache, M.; Musatov, S.; Flajolet, M.; et al. Reversal of Depressed Behaviors in Mice by P11 Gene Therapy in the Nucleus Accumbens. Sci. Transl. Med. 2010, 2, 54ra76.
  71. Svenningsson, P.; Greengard, P. P11 (S100A10)—An Inducible Adaptor Protein That Modulates Neuronal Functions. Curr. Opin. Pharmacol. 2007, 7, 27–32.
  72. Seo, J.-S.; Zhong, P.; Liu, A.; Yan, Z.; Greengard, P. Elevation of P11 in Lateral Habenula Mediates Depression-like Behavior. Mol. Psychiatry 2018, 23, 1113–1119.
  73. Becerril-Villanueva, E.; Olvera-Alvarez, M.I.; Alvarez-Herrera, S.; Maldonado-García, J.L.; López-Torres, A.; Ramírez-Marroquín, O.A.; González-Ruiz, O.; Nogueira-Fernández, J.M.; Mendoza-Contreras, J.M.; Sánchez-García, H.O.; et al. Screening of SERT and P11 mRNA Levels in Airline Pilots: A Translational Approach. Front. Psychiatry 2022, 13, 859768.
  74. Singh, P.; Ali, S.A. Multifunctional Role of S100 Protein Family in the Immune System: An Update. Cells 2022, 11, 2274.
  75. Tong, L.; Lan, W.; Lim, R.R.; Chaurasia, S.S. S100A Proteins as Molecular Targets in the Ocular Surface Inflammatory Diseases. Ocul. Surf. 2014, 12, 23–31.
  76. Bagheri-Hosseinabadi, Z.; Abbasi, M.; Kahnooji, M.; Ghorbani, Z.; Abbasifard, M. The Prognostic Value of S100A Calcium Binding Protein Family Members in Predicting Severe Forms of COVID-19. Inflamm. Res. 2022, 71, 369–376.
  77. MacLeod, T.J.; Kwon, M.; Filipenko, N.R.; Waisman, D.M. Phospholipid-Associated Annexin A2-S100A10 Heterotetramer and Its Subunits: Characterization of The Interaction with Tissue Plasminogen Activator, Plasminogen, and Plasmin. J. Biol. Chem. 2003, 278, 25577–25584.
  78. Brownstein, C.; Deora, A.B.; Jacovina, A.T.; Weintraub, R.; Gertler, M.; Khan, K.M.F.; Falcone, D.J.; Hajjar, K.A. Annexin II Mediates Plasminogen-Dependent Matrix Invasion by Human Monocytes: Enhanced Expression by Macrophages. Blood 2004, 103, 317–324.
  79. Dassah, M.; Deora, A.B.; He, K.; Hajjar, K.A. The Endothelial Cell Annexin A2 System and Vascular Fibrinolysis. Gen. Physiol. Biophys. 2009, 28, F20–F28.
  80. Hitchcock, J.K.; Katz, A.A.; Schäfer, G. Dynamic Reciprocity: The Role of Annexin A2 in Tissue Integrity. J. Cell Commun. Signal. 2014, 8, 125–133.
  81. Choi, K.; Fogg, D.K.; Yoon, C.; Waisman, D.M. P11 Regulates Extracellular Plasmin Production and Invasiveness of HT1080 Fibrosarcoma Cells. FASEB J. 2003, 17, 235–246.
  82. Lokman, N.A.; Ween, M.P.; Oehler, M.K.; Ricciardelli, C. The Role of Annexin A2 in Tumorigenesis and Cancer Progression. Cancer Microenviron. 2011, 4, 199–208.
  83. O’Connell, P.A.; Surette, A.P.; Liwski, R.S.; Svenningsson, P.; Waisman, D.M. S100A10 Regulates Plasminogen-Dependent Macrophage Invasion. Blood 2010, 116, 1136–1146.
  84. Phipps, K.D.; Surette, A.P.; O’Connell, P.A.; Waisman, D.M. Plasminogen Receptor S100A10 Is Essential for the Migration of Tumor-Promoting Macrophages into Tumor Sites. Cancer Res. 2011, 71, 6676–6683.
  85. Shiozawa, Y.; Havens, A.M.; Jung, Y.; Ziegler, A.M.; Pedersen, E.A.; Wang, J.; Wang, J.; Lu, G.; Roodman, G.D.; Loberg, R.D.; et al. Annexin II/Annexin II Receptor Axis Regulates Adhesion, Migration, Homing, and Growth of Prostate Cancer. J. Cell. Biochem. 2008, 105, 370–380.
  86. Zhang, L.; Fogg, D.K.; Waisman, D.M. RNA Interference-Mediated Silencing of the S100A10 Gene Attenuates Plasmin Generation and Invasiveness of Colo 222 Colorectal Cancer Cells. J. Biol. Chem. 2004, 279, 2053–2062.
  87. Zhong, L.; Wei, K.; Yang, X.; Zhang, L.; Zhou, X.; Pan, H.; Li, J.; Chen, W.; Zhang, Z. Increased Expression of Annexin A2 in Oral Squamous Cell Carcinoma. Arch. Oral. Biol. 2009, 54, 17–25.
  88. Fujiwara, N.; Kobayashi, K. Macrophages in Inflammation. CDTIA 2005, 4, 281–286.
  89. Cox, G.; Crossley, J.; Xing, Z. Macrophage Engulfment of Apoptotic Neutrophils Contributes to the Resolution of Acute Pulmonary Inflammation in Vivo. Am. J. Respir. Cell Mol. Biol. 1995, 12, 232–237.
  90. Miller, V.A.; Madureira, P.A.; Kamaludin, A.A.; Komar, J.; Sharma, V.; Sahni, G.; Thelwell, C.; Longstaff, C.; Waisman, D.M. Mechanism of Plasmin Generation by S100A10. Thromb. Haemost. 2017, 117, 1058–1071.
  91. Kassam, G.; Choi, K.-S.; Ghuman, J.; Kang, H.-M.; Fitzpatrick, S.L.; Zackson, T.; Zackson, S.; Toba, M.; Shinomiya, A.; Waisman, D.M. The Role of Annexin II Tetramer in the Activation of Plasminogen. J. Biol. Chem. 1998, 273, 4790–4799.
  92. Miles, L.A.; Dahlberg, C.M.; Plescia, J.; Felez, J.; Kato, K.; Plow, E.F. Role of Cell-Surface Lysines in Plasminogen Binding to Cells: Identification of α-Enolase as a Candidate Plasminogen Receptor. Biochemistry 1991, 30, 1682–1691.
  93. Miles, L.A.; Andronicos, N.M.; Chen, E.I.; Baik, N.; Bai, H.; Parmer, C.M.; Lighvani, S.; Nangia, S.; Kiosses, W.B.; Kamps, M.P.; et al. Identification of the Novel Plasminogen Receptor, Plg-RKT. In Proteomics—Human Diseases and Protein Functions; IntechOpen: London, UK, 2012; ISBN 978-953-307-832-8.
  94. Das, R.; Burke, T.; Plow, E.F. Histone H2B as a Functionally Important Plasminogen Receptor on Macrophages. Blood 2007, 110, 3763–3772.
  95. Swisher, J.F.A.; Burton, N.; Bacot, S.M.; Vogel, S.N.; Feldman, G.M. Annexin A2 Tetramer Activates Human and Murine Macrophages through TLR4. Blood 2010, 115, 549–558.
  96. Hajjar, K.A. The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity. Trans. Am. Clin. Climatol. Assoc. 2015, 126, 144–155.
  97. Lin, L.; Wu, C.; Hu, K. Tissue Plasminogen Activator Activates NF-κB through a Pathway Involving Annexin A2/CD11b and Integrin-Linked Kinase. J. Am. Soc. Nephrol. 2012, 23, 1329–1338.
  98. Bharadwaj, A.; Bydoun, M.; Holloway, R.; Waisman, D. Annexin A2 Heterotetramer: Structure and Function. Int. J. Mol. Sci. 2013, 14, 6259–6305.
  99. Hoesel, B.; Schmid, J.A. The Complexity of NF-κB Signaling in Inflammation and Cancer. Mol. Cancer 2013, 12, 86.
  100. Sansico, F.; Miroballo, M.; Bianco, D.S.; Tamiro, F.; Colucci, M.; Santis, E.D.; Rossi, G.; Rosati, J.; Di Mauro, L.; Miscio, G.; et al. COVID-19 Specific Immune Markers Revealed by Single Cell Phenotypic Profiling. Biomedicines 2021, 9, 1794.
  101. Gisby, J.S.; Buang, N.B.; Papadaki, A.; Clarke, C.L.; Malik, T.H.; Medjeral-Thomas, N.; Pinheiro, D.; Mortimer, P.M.; Lewis, S.; Sandhu, E.; et al. Multi-Omics Identify Falling LRRC15 as a COVID-19 Severity Marker and Persistent pro-Thrombotic Signals in Convalescence. Nat. Commun. 2022, 13, 7775.
  102. Gerke, V.; Moss, S.E. Annexins and Membrane Dynamics. Biochim. Biophys. Acta Mol. Cell Res. 1997, 1357, 129–154.
  103. König, J.; Prenen, J.; Nilius, B.; Gerke, V. The Annexin II-P11 Complex Is Involved in Regulated Exocytosis in Bovine Pulmonary Artery Endothelial Cells. J. Biol. Chem. 1998, 273, 19679–19684.
  104. Umbrecht-Jenck, E.; Demais, V.; Calco, V.; Bailly, Y.; Bader, M.-F.; Chasserot-Golaz, S. S100A10-Mediated Translocation of Annexin-A2 to SNARE Proteins in Adrenergic Chromaffin Cells Undergoing Exocytosis. Traffic 2010, 11, 958–971.
  105. Nakata, T.; Sobue, K.; Hirokawa, N. Conformational Change and Localization of Calpactin I Complex Involved in Exocytosis as Revealed by Quick-Freeze, Deep-Etch Electron Microscopy and Immunocytochemistry. J. Cell Biol. 1990, 110, 13–25.
  106. Senda, T.; Okabe, T.; Matsuda, M.; Fujita, H. Quick-Freeze, Deep-Etch Visualization of Exocytosis in Anterior Pituitary Secretory Cells: Localization and Possible Roles of Actin and Annexin II. Cell Tissue Res. 1994, 277, 51–60.
  107. Liu, L.; Tao, J.-Q.; Zimmerman, U.-J.P. Annexin II Binds to the Membrane of A549 Cells in a Calcium-Dependent and Calcium-Independent Manner. Cell. Signal. 1997, 9, 299–304.
  108. Neher, E.; Zucker, R.S. Multiple Calcium-Dependent Processes Related to Secretion in Bovine Chromaffin Cells. Neuron 1993, 10, 21–30.
  109. Chasserot-Golaz, S.; Vitale, N.; Sagot, I.; Delouche, B.; Dirrig, S.; Pradel, L.A.; Henry, J.P.; Aunis, D.; Bader, M.F. Annexin II in Exocytosis: Catecholamine Secretion Requires the Translocation of P36 to the Subplasmalemmal Region in Chromaffin Cells. J. Cell Biol. 1996, 133, 1217–1236.
  110. Sarafian, T.; Pradel, L.-A.; Henry, J.-P.; Aunis, D.; Bader, M.-F. The Participation of Annexin II (Calpactin I) in Calcium-Evoked Exocytosis Requires Protein Kinase C. J. Cell Biol. 1991, 114, 1135–1147.
  111. Bai, X.; Ran, J.; Zhao, X.; Liang, Y.; Yang, X.; Xi, Y. The S100A10–AnxA2 Complex Is Associated with the Exocytosis of Hepatitis B Virus in Intrauterine Infection. Lab. Investig. 2022, 102, 57–68.
  112. Taylor, J.R.; Skeate, J.G.; Kast, W.M. Annexin A2 in Virus Infection. Front. Microbiol. 2018, 9, 2954.
  113. Dziduszko, A.; Ozbun, M.A. Annexin A2 and S100A10 Regulate Human Papillomavirus Type 16 Entry and Intracellular Trafficking in Human Keratinocytes. J. Virol. 2013, 87, 7502–7515.
  114. Woodham, A.W.; Da Silva, D.M.; Skeate, J.G.; Raff, A.B.; Ambroso, M.R.; Brand, H.E.; Isas, J.M.; Langen, R.; Kast, W.M. The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection. PLoS ONE 2012, 7, e43519.
  115. Woodham, A.W.; Sanna, A.M.; Taylor, J.R.; Skeate, J.G.; Da Silva, D.M.; Dekker, L.V.; Kast, W.M. Annexin A2 Antibodies but Not Inhibitors of the Annexin A2 Heterotetramer Impair Productive HIV-1 Infection of Macrophages in Vitro. Virol. J. 2016, 13, 187.
  116. Chehab, T.; Santos, N.C.; Holthenrich, A.; Koerdt, S.N.; Disse, J.; Schuberth, C.; Nazmi, A.R.; Neeft, M.; Koch, H.; Man, K.N.M.; et al. A Novel Munc13-4/S100A10/Annexin A2 Complex Promotes Weibel–Palade Body Exocytosis in Endothelial Cells. MBoC 2017, 28, 1688–1700.
  117. Holthenrich, A.; Gerke, V. Regulation of Von-Willebrand Factor Secretion from Endothelial Cells by the Annexin A2-S100A10 Complex. Int. J. Mol. Sci. 2018, 19, 1752.
  118. Celma, C.C.P.; Roy, P. Interaction of Calpactin Light Chain (S100A10/P11) and a Viral NS Protein Is Essential for Intracellular Trafficking of Nonenveloped Bluetongue Virus. J. Virol. 2011, 85, 4783–4791.
  119. Beaton, A.R.; Rodriguez, J.; Reddy, Y.K.; Roy, P. The Membrane Trafficking Protein Calpactin Forms a Complex with Bluetongue Virus Protein NS3 and Mediates Virus Release. Proc. Natl. Acad. Sci. USA 2002, 99, 13154–13159.
  120. Woodham, A.W.; Taylor, J.R.; Jimenez, A.I.; Skeate, J.G.; Schmidt, T.; Brand, H.E.; Da Silva, D.M.; Kast, W.M. Small Molecule Inhibitors of the Annexin A2 Heterotetramer Prevent Human Papillomavirus Type 16 Infection. J. Antimicrob. Chemother. 2015, 70, 1686–1690.
  121. Donato, R.; Cannon, B.R.; Sorci, G.; Riuzzi, F.; Hsu, K.; Weber, D.J.; Geczy, C.L. Functions of S100 Proteins. Curr. Mol. Med. 2013, 13, 24–57.
  122. Ling, F.; Lu, Q. S100 Calcium-Binding Protein A10 Contributes to Malignant Traits in Osteosarcoma Cells by Regulating Glycolytic Metabolism via the AKT/mTOR Pathway. Bioengineered 2022, 13, 12298–12308.
  123. Li, Y.; Li, X.-Y.; Li, L.-X.; Zhou, R.-C.; Sikong, Y.; Gu, X.; Jin, B.-Y.; Li, B.; Li, Y.-Q.; Zuo, X.-L. S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer. Front. Cell Dev. Biol. 2020, 8, 559486.
  124. Lin, H.; Yang, P.; Li, B.; Chang, Y.; Chen, Y.; Li, Y.; Liu, K.; Liang, X.; Chen, T.; Dai, Y.; et al. S100A10 Promotes Pancreatic Ductal Adenocarcinoma Cells Proliferation, Migration and Adhesion through JNK/LAMB3-LAMC2 Axis. Cancers 2022, 15, 202.
  125. Kirtonia, A.; Pandey, A.K.; Ramachandran, B.; Mishra, D.P.; Dawson, D.W.; Sethi, G.; Ganesan, T.S.; Koeffler, H.P.; Garg, M. Overexpression of Laminin-5 Gamma-2 Promotes Tumorigenesis of Pancreatic Ductal Adenocarcinoma through EGFR/ERK1/2/AKT/mTOR Cascade. Cell. Mol. Life Sci. 2022, 79, 362.
  126. Wang, X.; Huang, H.; Sze, K.M.-F.; Wang, J.; Tian, L.; Lu, J.; Tsui, Y.-M.; Ma, H.T.; Lee, E.; Chen, A.; et al. S100A10 Promotes HCC Development and Progression via Transfer in Extracellular Vesicles and Regulating Their Protein Cargos. Gut 2023, 72, 1370–1384.
  127. Wei, R.; Feng, O.Q.; Hui, Y.Z.; Huang, X.; Ping, L.S. Prognostic Value of the S100 Calcium-Binding Protein Family Members in Hepatocellular Carcinoma. Biosci. Rep. 2023, 43, BSR20222523.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback